Outcomes4Me raises $21M to scale AI-driven cancer care platform
The company aims to enhance its direct-to-patient cancer care platform and expand globally following its latest $21 million investment round.
Silas Davenport 
Outcomes4Me, a Boston-based healthtech company, has secured $21 million in new funding to support its AI-powered platform designed for cancer patients. The round introduces new investor Salica Investments, based in London, and includes continued support from previous backers such as Labcorp Venture Fund, Forecast Labs, Northpond Ventures, Sierra Ventures, Asset Management Ventures, IRA Capital, and Merstal LTD. With this latest round, the company’s total funding has reached $38 million.
CEO focuses on global reach and data precision
According to Dr. Maya R. Said, Founder and CEO of Outcomes4Me, the platform’s mission is to support cancer patients by offering them real-time, AI-enhanced insights throughout their treatment journey. She noted that over 280,000 users are already engaging with the platform, benefiting from tools that integrate clinical guidelines, genomic analysis, symptom tracking, and trial matching features in a single interface. Dr. Said emphasized that the latest investment will allow the company to broaden access, deepen its AI capabilities, and drive its commercial growth internationally.
Collaborations with top pharma companies
Since its commercial debut in 2022, Outcomes4Me has established itself as a strategic partner to life sciences companies, offering data-driven tools to connect treatments with patients more effectively. The company now collaborates with seven of the ten largest cancer pharmaceutical companies worldwide, reflecting strong industry interest in more tailored oncology solutions. Its technology enables the generation of proprietary patient-level datasets, which are increasingly valuable for clinical and commercial applications.
International expansion and technology growth
The newly acquired funds will support a number of strategic initiatives, including expanding into new cancer types and international markets, enhancing its AI algorithms, and growing its real-world data capabilities. The company also plans to strengthen its partnerships with health systems and develop new business models that align with evidence-based outcomes.
Industry recognition supports long-term vision
Outcomes4Me has received more than 15 industry awards over the past three years. An independent study published in Current Oncology recognized the company’s app as the highest-rated among over 3,000 digital tools for adult cancer patients. Additionally, the company climbed to #12 in the Inc. Regionals Northeast 2025 ranking and was represented by Dr. Said as a finalist in the EY Entrepreneur of the Year awards for the New England region.
As the platform continues to evolve, Outcomes4Me is positioning itself to play a more influential role in digital oncology, focusing on real-world evidence, smarter AI, and a more patient-centric cancer care experience at a global scale.
